TOP TEN perturbations for 388_at (Homo sapiens)
Organism: Homo sapiens
Gene: 388_at
Selected probe(set): 1568629_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 388_at (1568629_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):2.0765238Number of Samples:2 / 4
| Experimental | glioma study 17 ( small cell glioblastoma; unsorted) |
| Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)
Relative Expression (log2-ratio):1.9737368Number of Samples:15 / 2
| Experimental | uterine/pelvic pathology study 2 (pro. MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | uterine/pelvic pathology study 2 (late se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
hepatoblastoma study 1 (NOS) / normal liver tissue
Relative Expression (log2-ratio):1.947999Number of Samples:5 / 5
| Experimental | hepatoblastoma study 1 (NOS) |
| Liver tumor tissue samples from children with hepatoblastoma (NOS). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
| Control | normal liver tissue |
| Normal liver tissue samples. |
sickle cell disease study 2 (Globin red.) / normal blood sample
Relative Expression (log2-ratio):1.9028168Number of Samples:5 / 5
| Experimental | sickle cell disease study 2 (Globin red.) |
| Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclear™-Human kit. | |
| Control | normal blood sample |
| Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit including an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclearTM-Human kit. |
sickle cell disease study 2 (Pax) / normal blood sample
Relative Expression (log2-ratio):1.8756933Number of Samples:5 / 5
| Experimental | sickle cell disease study 2 (Pax) |
| Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion step. | |
| Control | normal blood sample |
| Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit followed by an on-column DNase digestion step. |
hepatoblastoma study 1 (epithelial mixed) / normal liver tissue
Relative Expression (log2-ratio):1.8709211Number of Samples:12 / 5
| Experimental | hepatoblastoma study 1 (epithelial mixed) |
| Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
| Control | normal liver tissue |
| Normal liver tissue samples. |
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):-1.8312616Number of Samples:8 / 8
| Experimental | PMA; ionomycine study 2 |
| CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
| Control | unstimulated CD4 memory T-cell sample |
| Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
hepatoblastoma study 1 (mixed epithelial and mesenchymal) / normal liver tissue
Relative Expression (log2-ratio):1.8178282Number of Samples:4 / 5
| Experimental | hepatoblastoma study 1 (mixed epithelial and mesenchymal) |
| Liver tumor tissue samples from children with hepatoblastoma (mesenchymal type (MEM-HB); mixed epithelial and mesenchymal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group. | |
| Control | normal liver tissue |
| Normal liver tissue samples. |
cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample
Relative Expression (log2-ratio):-1.8055611Number of Samples:4 / 4
| Experimental | cicloheximide study 1 |
| MCF7 breast cancer cells were treated for 1h with cicloheximide (10 ug/ml) before vehicle treatment (0.1% ethanol) for 24h. ATC code:--- | |
| Control | vehicle (DMSO) treated MCF-7 cell sample |
| MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h. |
estradiol; cicloheximide study 1 / vehicle (DMSO) treated MCF-7 cell sample
Relative Expression (log2-ratio):-1.798377Number of Samples:4 / 4
| Experimental | estradiol; cicloheximide study 1 |
| MCF7 breast cancer cells were treated with cicloheximide (10 ug/ml) for 1 hour before hormonal treatment with 17{beta}-estradiol (E2, 25 nM) for 24 hours. ATC code: | |
| Control | vehicle (DMSO) treated MCF-7 cell sample |
| MCF7 breast cancer cells treated with vehicle DMSO (0.1%) for 1h and subsequently with vehicle (0.1% ethanol) for 24h. |
Organism: Homo sapiens
Gene: 388_at
Selected probe(set): 201422_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 388_at (201422_at) across 6674 perturbations tested by GENEVESTIGATOR:
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-5.027481Number of Samples:2 / 2
| Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
| Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Relative Expression (log2-ratio):4.6728096Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). |
glioma study 16 (LN-319) / normal astrocyte sample
Relative Expression (log2-ratio):4.6473417Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-319) |
| Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.6033955Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):4.19188Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
T. cruzi study 1 (HMVEC; 24h; bottom) / mock infected cardiac microvascular endothelial cell sample (24h; bottom)
Relative Expression (log2-ratio):4.043433Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (HMVEC; 24h; bottom) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. | |
| Control | mock infected cardiac microvascular endothelial cell sample (24h; bottom) |
| Human cardiac microvascular endothelial cells (HMVECs) grown in the transwell bottom, mock-infected and harvested 24 hours post mock infection with 2% FBS medium. Cells were maintained in endothelial cell basal medium-2 and endothelial cell growth supplements including 5% FBS. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):4.0116787Number of Samples:2 / 13
| Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). |
skin transplantation study 1 (3d) / split-thickness skin grafting study 1
Relative Expression (log2-ratio):3.987836Number of Samples:6 / 6
| Experimental | skin transplantation study 1 (3d) |
| Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 3 days after surgery. | |
| Control | split-thickness skin grafting study 1 |
| Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting. |
PMA study 2 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):3.7566452Number of Samples:3 / 2
| Experimental | PMA study 2 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
T. cruzi study 1 (BJ; 24h; bottom) / mock infected foreskin fibroblast (BJ) sample (24h; bottom)
Relative Expression (log2-ratio):3.7381926Number of Samples:2 / 2
| Experimental | T. cruzi study 1 (BJ; 24h; bottom) |
| Foreskin fibroblast (BJ) cells grown in the transwell bottom, infected with Trypanosoma cruzi trypomastigotes for 2 hours (10exp8/ml) and harvested 24 hours post infection. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. | |
| Control | mock infected foreskin fibroblast (BJ) sample (24h; bottom) |
| Foreskin fibroblast (BJ) cells grown in the transwell bottom, mock-infected and harvested 24 hours post mock infection with 2% FBS medium. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. |